The combination of Cisbio’s expertise with CyBio’s flexible and reliable workstation will enable Cisbio to reinforce its service offering, which includes custom assay development for the creation and optimization of HTRF assays. HTRF is Cisbio’s highly sensitive, robust technology for the detection of molecular interactions that is widely used by the pharmaceutical industry for the high throughput screening stage of drug development. The CyBio workstation, a customized, modular, multi-functional automation platform for high throughput applications, allows for efficient testing under different assay conditions and applied research using high-density plate formats including 384-w low volume and 1536-w, the standards in today’s high throughput screening industry.
“Services are an integral part of our business and we strive to optimize HTRF’s flexibility and miniaturization capabilities with state-of-the art equipment that is well-adapted to an assay development platform,” said François Degorce, director of marketing, Cisbio Bioassays. “We selected CyBio’s robotic workstation because of their reputation for supplying high-quality and precise dispensing materials, as well as their reactive customer service, a concept which Cisbio both understands and values.”
Each CyBio workstation is individually designed using CyBio equipment and integrated parts. Starting with a base module, the workstation is customized to meet specific process, throughput and capacity requirements. Its integrated components, such as pipettors, incubators, readers, dispensers and other automation modules, work together to automate an assay from set-up to data collection.
About Cisbio Bioassays
Cisbio Bioassays is a global developer of products and technologies used in in vitro diagnostics and assay development for drug screening procedures. The company pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF®, a highly sensitive, robust technology for the detection of molecular interactions and widely used by the pharmaceutical industry for the high throughput screening stage of drug development. In addition, Cisbio produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs).
Headquartered in Bagnols-sur-Cèze, France, with facilities in Bedford, MA, U.S.A. and a network of distributors worldwide, Cisbio is a member of the Belgium-based IBA group. IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. Please visit www.htrf.com and www.iba-worldwide.com for more information about Cisbio and IBA.
HTRF® is a registered trademark of Cisbio Bioassays.
About CyBio AG
With almost 20 years of experience, CyBio is a leading player of high quality liquid handling technologies. In the pharmaceutical and life science industries, CyBio's products enjoy the highest reputation for precision, reliability and simplicity. From standalone CyBi®-Well pipettors up to fully customized solutions CyBio provides reliable, precise and user-friendly automated systems for a wide range of application and throughput needs in Life Sciences and Drug Discovery research. Moreover, CyBio's Customized Solutions Team designs, produces and installs fully automated systems tailored to client's application, throughput and capacity requirements.
Headquartered in Jena, Germany, CyBio employs more than 150 employees worldwide. Its products are sold by a dedicated sales force and a global network of distributors. CyBio's clients are leading pharmaceutical and biotechnology companies, as well as academic research institutes.
Visit www.cybio-ag.com for more information.
